MedTrace Logo

Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

NCT00784212 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2016-09-23

No results posted yet for this study

Summary

This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Conditions

  • Photosensitive Epilepsy

Interventions

DRUG

BGG492

DRUG

BGG492

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis Investigator Site

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00784212 on ClinicalTrials.gov